



Continuing Education Credit Information

Program Description and Learning Objectives
Accreditation Information, Types of Credit, Claiming Credit
Scientific Program
Disclosures

Program Description and Learning Objectives

Target Audience

The educational design of this activity addresses the needs of healthcare professionals (physicians, surgeons, pharmacists, nurses, and others) and researchers working in the field of transplantation.

Educational Objectives

The following overarching objectives and more specific goals have been identified for this meeting. Having participated in this meeting, attendees will be able to:

- Describe how other medical fields such as hematology and cardiology have developed technologies and biomarkers to facilitate personalized care.
- Describe interventions to optimize the candidacy of individuals with organ failure who present challenges to successful transplantation such as obesity, malnutrition, frailty, or lack of a social support system.
- Describe the challenges and potential strategies to match donated organs to appropriate recipients without disadvantaging the individual or increasing the number of discarded organs.
- Describe the evolving landscape of transplant diagnostics to detect alloimmune mediated graft injury including the intended use of these diagnostics to detect rejection, predict rejection, or allow minimization of immunosuppression following transplantation.
- Describe how in the future the development of validated biomarkers may be used to guide the selection of optimized immunosuppressive regimens for individuals of differing clinical or molecular phenotypes.
- Describe how minimizing HLA/epitope mismatching combined with assays to more fully characterize humoral and cellular immunity may lead to risk stratification of individual recipients and personalized care plans.

Statement of Need/Program Overview

As the organ shortage has become more severe, ideal requirements for selection of organ donors are far from feasible. Organs that previously would have been considered unsuitable for transplantation, are, with advances in technology, now being used. This new class of organ donor, the “marginal” donor, may include older donors, those with chronic disease, or in selected cases those with infectious diseases. CEoT approaches the topic of marginal organs to increase the organ pool by reviewing administrative strategies to encourage centers to use marginal organs, sharing best practices to safely use marginal organs, and exploring interventions in the deceased organ donor to improve organ quality as well as optimal strategies to repair organs ex-vivo.

A Focus on Heart and Lung Transplant with a Dedicated Parallel Heart Track and Lung Track

At CEOT, experts in the field will navigate attendees through challenges of heart or lung allocation via panel discussions, debates, and case studies.

Accreditation Information, Types of Credit, Claiming Credit

This activity is jointly provided by Global Education Group and the American Society of Transplantation.



This activity is supported by educational grants from Novartis and Shire.

Commercial support provided by Angel MedFlight, Astellas, CareDx, Cedars-Sinai Heart Institute, CSL Behring, Hansa BioPharma, Novartis, OmniLife, Inc. (formerly HealthTech Solutions), One Lambda, Sanofi Genzyme, TAI Diagnostics, Takeda (Shire is now a part of Takeda) and Veloxis

How to Claim Credit

Following the meeting, all participants will receive a link to an online evaluation form. After completing this evaluation, participants may claim a certificate noting the appropriate amount of credit or request a general certificate of attendance.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and American Society of Transplantation. Global is accredited by the ACCME to provide continuing medical education for physicians.

Global Education Group designates this live activity for 15.75 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.



Global Education Group designates this continuing education activity for 15.75 contact hour(s) (1.575 CEUs) of the Accreditation Council for Pharmacy Education.

Please see www.myAST.org/CEOT for full ACPE information and UAN numbers.

Credit Hours	Date and Time	Title	UAN
1.5	2/21/2019 – 2:00-3:30 PM	<i>Session 1: Personalized Medicine – How Do We Catch Up?</i>	0530-9999-19-017-L01-P
1.5	2/21/2019 – 4:00-5:30 PM	<i>Session 2: Shark Tank: George Lucas Foresees the Future of Transplantation – All Things Omics</i>	0530-9999-19-018-L01-P
2.75	2/22/2019 – 7:30-10:15 AM	<i>Session 3: Option 1: Personalized Organ Allocation - The Right Organ, For the Right Recipient, at the Right Time</i>	0530-9999-19-019-L01-P
2.00	2/22/2019 – 8:15-10:15 AM	<i>Session 3: Option 2: To Infinity and Beyond - Moving Past the Biopsy in Heart Transplantation</i>	0530-9999-19-020-L01-P
2.0	2/22/2019 – 8:15-10:15 AM	<i>Session 3: Option 3: Who's Monitoring the Monitor in Lung Transplantation Rejection Surveillance?</i>	0530-9999-19-021-L01-P
2.0	2/22/2019 - 10:30-12:30 PM	<i>Session 4: Option 1: With all Our Drugs Why Can't We Develop Evidence-Based, Individualized Immunosuppression?</i>	0530-9999-19-022-L01-P
2.0	2/22/2019 - 10:30-12:30 PM	<i>Session 4: Option 2: Customized Immunosuppression - Why Didn't I Think of That?</i>	0530-9999-19-023-L01-P
2.0	2/22/2019 - 10:30-12:30 PM	<i>Session 4: Option 3: Individualizing Immunosuppression - Will We Get There in Lung Transplantation?</i>	0530-9999-19-024-L01-P
1.0	2/22/2019 - 2:30-4:00 PM	<i>Session 5: Personalized Aftercare – Can It Be That Hard?</i>	0530-9999-19-025-L01-P
1.5	2/22/2019 – 4:00-5:30 PM	<i>Session 6: Personalized Strategies to Improve Access and Outcomes in Patients</i>	0530-9999-19-026-L01-P

		<i>of African Ancestry and Other Populations at Risk for a Poor Outcome</i>	
2.0	2/23/2019 – 8:30-10:30 AM	<i>Session 7: Option 1: Back to the Future – Beginning with HLA to Personalize Care</i>	0530-9999-19-027-L01-P
2.0	2/23/2019 – 8:30-10:30 AM	<i>Session 7: Option 2: Thoracic Cases</i>	0530-9999-19-028-L01-P
1.5	2/23/2019 – 12:00-1:30 PM	<i>Session 8: Transplant Center Practice – Is Variety the Spice of Life?</i>	0530-9999-19-029-L01-P
2.0	2/23/2019 – 1:30-3:30 PM	<i>Session 9: Trailblazers - Programs with Specialized Programs of Patient Care</i>	0530-9999-19-030-L01-P

This is a knowledge-based activity.

Nursing Continuing Education

Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's COA.

This educational activity for 15.75 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Questions about Accreditation

For information about the accreditation of this program, please contact Global at 303-395-1782 or CME@globaleducationgroup.com.

Scientific Program

The complete 2019 CEOT program schedule is available at <https://www.myast.org/meetings/cutting-edge-transplantation/2019/2019-ceot-program>

Conflict of Interest Disclosures

A list of faculty is available at <https://www.myast.org/meetings/cutting-edge-transplantation/2019/speaker-information>.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following **faculty** reported financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty	Reported Disclosed Relationships
Andrew B. Adams*	Nothing to Disclose
Matthew Albert	Consultant/Independent Contractor: Genentech - employee
David Baran	Consultant/Independent Contractor: Getinge, Livanova, Novartis
Amit Bery	Nothing to Disclose
Ankit Bharat	Nothing to Disclose
Geetha Bhat	Nothing to Disclose
Sangeeta Bhorade	Nothing to Disclose
Roy Bloom*	Consultant/Independent Contractor: Veloxis Grant/Research Support: Veloxis, CareDx, Shire Honoraria: CSL Behring Other/Royalty: UpToDate
Emily Blumberg	Nothing to Disclose

Name of Faculty	Reported Disclosed Relationships
Robert A. Bray	Nothing to Disclose
Kimberly A. Brown	Consultant/Independent Contractor: Pfizer, Merck, Gilead Grant/Research Support: Valeant, Allergan, Gilead, Novartis
Marie Budev	Nothing to Disclose
Juan Carlos Caicedo	Nothing to Disclose
Kevin Clerkin	Nothing to Disclose
Daniel Dilling	Nothing to Disclose
Jeffrey D. Edelman	Nothing to Disclose
MaryJane Farr	Nothing to Disclose
Barry Fine	Nothing to Disclose
David Foley*	Nothing to Disclose
Mandy Ford	Consultant/Independent Contractor: Veloxis Pharmaceuticals
Richard Formica*	Nothing to Disclose
John Friedewald	Nothing to Disclose
Jon Friedman	Nothing to Disclose
Howard Gebel	Nothing to Disclose
John Gill*	Consultant/Independent Contractor: Sanofi
Elisa Gordon	Nothing to Disclose
Cynthia Gries	Nothing to Disclose
Ramsey Hachem	Consultant/Independent Contractor: Theravance, Vectura Grant/Research Support: Therakos, Bristol Myers Squibb
Shelley Hall	Nothing to Disclose
Philip Halloran	Grant/Research Support: Mendez National Institute of Transplantation Foundation Honoraria: Thermo Fisher Scientific Stock Shareholder: Transcriptome Sciences Inc.
Peter Heeger	Grant/Research Support: Alexion
Julie K. Heimbach	Nothing to Disclose
Stanley Jordan	Consultant/Independent Contractor: CSL Behring, Hansa Medical, CareDx, Vitaeris Grant/Research Support: CSL Behring, Hansa Medical, CareDx, Vitaeris Stock Shareholder: CareDx
Michelle Josephson*	Nothing to Disclose
Dixon Kaufman	Nothing to Disclose
Kiran Kaur Khush	Consultant/Independent Contractor: CareDx, Inc. Grant/Research Support: CareDx, Inc.
Allan D. Kirk	Nothing to Disclose
Jon Kobashigawa*	Consultant/Independent Contractor: CareDx, Inc. Grant/Research Support: Molecular Microscope
Chitaru Krihara	Nothing to Disclose
Deborah Levine	Nothing to Disclose
Josh Levitsky*	Consultant/Independent Contractor: Transplant Genomics Inc. Grant/Research Support: Novartis Honoraria: Novartis Stock Shareholder: Transplant Genomics Inc.
Alexandre Loupy	Nothing to Disclose
Roslyn Mannon	Grant/Research Support: Quark, Mallinckrodt, Transplant Genomics Honoraria: CSL-Behring
Elizabeth McNally	Consultant/Independent Contractor: Exonics, Invitae, AstraZeneca Grant/Research: Solid Biosciences Stock Shareholder: Ikaika Therapeutics
Ulf Meier-Kriesche	Consultant/Independent Contractor: Veloxis Honoraria: Veloxis Other/Royalty: Veloxis
Joseph Keith Melancon	Consultant/Independent Contractor: Veloxis
Michael Mengel	Consultant/Independent Contractor: Shire Inc.
Yasbanoo Moayed	Nothing to Disclose
Thalachallour Mohanakumar	Nothing to Disclose
Julio Montaner	Nothing to Disclose
David Nelson	Nothing to Disclose
Kenneth Newell*	Consultant/Independent Contractor: Medeor, Veloxis, CSL Behring, Sanofi, Mallinckrodt (each < \$5,000. Estimated total about \$15,000)
Peter Nickerson*	Consultant/Independent Contractor: Vitaeris Inc., Astellas Pharma Global Development Inc. Honoraria: Astellas Canada Inc., One Lambda Inc.

Name of Faculty	Reported Disclosed Relationships
Mark Nicolls	Nothing to Disclose
Jonah Odum	Nothing to Disclose
Jignesh Patel	Consultant/Independent Contractor: Pfizer, Alnylam, Mallinckrodt Pharmaceuticals, AstraZeneca Grant/Research Support: Alnylam, Pfizer, Alexion Honoraria: Alnylam, Akcea, Therakos
Neil R. Powe	Nothing to Disclose
Minnie Sarwal	Nothing to Disclose
Deirdre Sawinski	Nothing to Disclose
Jesse Schold*	Nothing to Disclose
Marina Serper	Nothing to Disclose
Kevin S Shah	Nothing to Disclose
Palak Shah	Consultant/Independent Contractor: NuPulseCV Grant/Research Support: AHA/Enduring Hearts Scientist Development Grant, Medtronic, Merck, Haemonetics
Anat Tambur*	Consultant/Independent Contractor: Astellas
Giuliano Testa	Nothing to Disclose
Srinivas Titte	Nothing to Disclose
Nicole Turgeon	Consultant/Independent Contractor: Natera
Nicole Valenzuela	Nothing to Disclose
Marcel van den Brink	Consultant/Independent Contractor: Seres Therapeutics Grant/Research Support: This work was supported by National Cancer Institute (NCI) grants R01-CA228358-01 (M.R.M.v.d.B.), R01-CA228308-01 (M.R.M.v.d.B.), Memorial Sloan Kettering Cancer Center Support Grant/Core grant P30 CA008748, and Project 4 of P1-CA03766-39 (M.R.M.v.d.B.) as well as National Heart, Lung and Blood Institute (NHLBI) grants R01-HL123340-04 (K. Cadwell), and R01-HL125571-04 (A.M. Hanash). Additional support was received from the National Institute of Aging grant Project 2 of P01-AG052359-02 (M.R.M.v.d.B.) and by the Tri-Institutional Stem Cell Initiative award 2016-013 (S. Rafii). Support was also received from The Lymphoma Foundation, the Susan and Peter Solomon Divisional Genomics Program, the Parker Institute for Cancer Immunotherapy at MSKCC and the European Union's Seventh Framework Programme for Research, Technological Development, and Demonstration under grant agreement 602587. Honoraria: Seres Therapeutics, Flagship Ventures, Novartis, Evelo, Jazz Pharmaceuticals, Therakos, Amgen, merck & Co, Inc., Acute Leukemia Forum (ALF) and DKMS Medical Council (Board) Stock Shareholder: Seres Therapeutics Other/Royalty: MSKCC, IP Licensure: SK2018-086, SK2018-033, SK2017-082, SK2017-047, SK2017-008, SK2016-044, SK2016-013, SK2015-074, SK2015-032, SK2014-114, SK2013-098, SK2014-086, SK2014-063, SK2012-101, SK2012-051, SK2012-042, SK2011-049, SK2011-015, SK 958, SK1476, SK1316
Flavio Vincenti	Grant/Research Support: Pfizer, Astellas, merck, Bristol-Myers Squibb, Angion, Genentech
Martin Zamora	Nothing to Disclose

*Program planning committee member

The following **planners and managers** reported financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager	Reported Financial Relationship
Ashley Marostica, RN, MSN	Nothing to disclose
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Carly Lihotz	Nothing to disclose
JoAnn Gwynn	Nothing to disclose
Randy Young	Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and American Society of Transplantation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

Registration fees were collected for this activity. No refunds are permitted after January 23rd, 2019.